Ferric Carboxymaltose is a prescription iron replacement medicine which was approved for its medical use on 26th July 2013.

Ferric Carboxymaltose Injection has been developed to treat iron deficiency anaemia in adult and paediatric patients who have not responded well to oral iron treatment. This injection also treats iron deficiency anaemia in adult patients with chronic kidney disease who are not dependent on dialysis.

Ferric Carboxymaltose is available as 2ml, 10ml and 20ml vials of injection in the doses 100mg, 500mg and 1000mg. Your healthcare provider will calculate the accurate dose and inject this medicine into your vein. The usual recommended dose for patients weighing more than 50kg is 15mg/kg of body weight or two 750mg injections separated by at least 7 days, thus forming a cumulative dose of 1500mg iron per course. The recommended dose for patients weighing less than 50 kg is 15mg/kg body weight in two doses separated by at least 7 days per course.

The common side effects that are likely to occur while you are on the treatment with Ferric Carboxymaltose Injection are nausea, hypertension, flushing, injection site reactions, dizziness, stomach pain, indigestion, vomiting, high heart rate, back pain and hypophosphatemia. If you experience any symptoms like allergic reactions, inflammation of veins, low blood pressure and breathing difficulty, report to your doctor immediately.

Your healthcare provider will observe for at least 30 minutes for signs and symptoms of hypersensitivity during and after injecting Ferric Carboxymaltose injection. you will also be monitored for changes in blood phosphate levels and blood pressure. Report to your doctor if you have had a history of heart failure, high blood pressure, liver problem, systemic lupus erythematosus or arthritis. Get immediate medical attention if you have breathlessness or lightheadedness.

Ferric Carboxymaltose injection is not recommended for use during pregnancy because the risk of hypersensitivity reactions can have serious consequences on the foetus. Ferric Carboxymaltose passes into the breast milk. However, it is not known whether this medicine would pose a risk to your baby. Tell your Healthcare provider before taking this injection if you are pregnant, think you could be pregnant, breastfeeding or planning to have a baby.

Ferric Carboxymaltose injection has the tendency to make you feel dizzy. So, it is advisable to avoid driving and handling machines during this treatment.

1. American Regent Inc., U.S. Food & Drug Administration, [Revised on Feb 2022] [Accessed on 23rd Aug 2022], https://daiichisankyo.us/prescribing-information-portlet/getDocument?product=IF&inline=true
2. Charmila et al., Efficacy and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia: A Multi-Center Real-World Study from India, Journal of Blood Medicine, Published on 8th June 2022, :13 303–313, [Accessed on 24th Aug 2022], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189149/pdf/jbm-13-303.pdf

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.